|
C12ORF26 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62436730732907E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.37427871702312E-14 |
| Normal-vs-Stage2 |
2.22520002424176E-09 |
| Normal-vs-Stage3 |
4.95625762653162E-12 |
| Normal-vs-Stage4 |
4.32986979603811E-15 |
| Stage1-vs-Stage2 |
5.303600E-01 |
| Stage1-vs-Stage3 |
7.401700E-02 |
| Stage1-vs-Stage4 |
5.82619999999201E-05 |
| Stage2-vs-Stage3 |
4.993400E-01 |
| Stage2-vs-Stage4 |
1.457910E-02 |
| Stage3-vs-Stage4 |
4.586400E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
2.08139999999801E-05 |
| Normal-vs-Asian |
1.16639999880874E-08 |
| Caucasian-vs-AfricanAmerican |
3.745600E-01 |
| Caucasian-vs-Asian |
3.464400E-01 |
| AfricanAmerican-vs-Asian |
8.619000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
7.51065876158918E-13 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
8.295900E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.0169999004338E-10 |
| Normal-vs-Age(41-60Yrs) |
6.31272811801864E-13 |
| Normal-vs-Age(61-80Yrs) |
1.19459997449667E-13 |
| Normal-vs-Age(81-100Yrs) |
1.03849999999461E-06 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.916200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.784300E-03 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.106000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.863500E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.381000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.391600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.464330E-03 |
| Classical-VS-Follicular |
8.318600E-01 |
| Classical-VS-Other |
6.406600E-01 |
| Classical-VS-Normal |
1.3372003504486E-10 |
| Tall-VS-Follicular |
1.674130E-02 |
| Tall-VS-Other |
3.203400E-01 |
| Tall-VS-Normal |
1.8517409827723E-12 |
| Follicular-VS-Other |
7.223800E-01 |
| Follicular-VS-Normal |
7.65519999612607E-08 |
| Other-VS-Normal |
1.963230E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.10460537886092E-11 |
| Normal-vs-N1 |
1.84596782304425E-12 |
| N0-vs-N1 |
3.494300E-02 |
|
|
